Tradestie Institutional Equity Comparison Engine

LYRA vs KROS โ€” Head-to-Head Terminal

6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.

Market Close: 2026-11-17 Buy Verdict Report Ask Alpha

Pillar 1 Executive Scorecard & Category Winner Tally

KROS Overall Edge

KROS Captures Institutional Edge (4โ€“0 Pillars ยท 8โ€“1 Matrix Metrics)

Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Keros Therapeutics, Inc. Common Stock (KROS) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, LYRA trades at N/M Forward P/E with -25032.0% operating margin (-87.2% YoY revenue) versus KROS at 48.8x Forward P/E and -172.4% operating margin (+180.5% YoY). In options structure, LYRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro) against KROS sits in CONSOLIDATION (10th %ile IV; Dealer Gamma Walls on Pro).

Valuation Winner KROS
LYRA N/M vs KROS 48.8x Fwd P/E
Growth & Margin Winner KROS
Op Margin -25032.0% vs -172.4% ยท YoY -87.2% vs +180.5%
Momentum & Technical Winner KROS
1Y -94.3% vs -35.3% ยท 52W Pos 1% vs 16%
Options & Structure Winner KROS
UNCLASSIFIED (N/A IV) vs CONSOLIDATION (10th %ile IV)
LYRA NASDAQ
Lyra Therapeutics, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$0.49
-62.5% 1D
Market Cap $2.3M
1M Return -62.5%
1Y Return -94.34%
Forward P/E N/M
Unified AI Score
52.2 / 100 HOLD
Tech 60.0 Fund 56.0 Flow 50.0 Mom 59.0
KROS NASDAQ
Keros Therapeutics, Inc. Common Stock
Pharmaceutical Preparations
$11.16
+11.27% 1D
Market Cap $202.1M
1M Return +0.9%
1Y Return -35.34%
Forward P/E 48.8x
Unified AI Score
52.2 / 100 HOLD
Tech 55.0 Fund 64.0 Flow 67.0 Mom 50.0

Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)

1Y Indexed Return: LYRA -94.34% KROS -35.34% Spread: +51.04 pp (KROS Lead)

Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant Revenue ($B) & Operating Margin (%)
Period LYRA Revenue KROS Revenue LYRA Op. Margin KROS Op. Margin Margin Edge
FY2019 N/A $10M N/A -105.6% KROS
FY2021 $0M $20M -15303.5% -280.5% KROS
FY2022 $0M N/A -4131.0% N/A LYRA
FY2023 $0M $0M -4308.1% -112543.7% LYRA
FY2024 $0M $0M -6280.8% -5939.0% KROS
FY2025 $0M $240M -7794.5% 27.7% KROS

Pillar 4 Head-to-Head Fundamental & Valuation Matrix

Matrix Tally: LYRA (1) vs KROS (8)
Institutional Metric LYRA KROS Criterion Row Winner
Market Capitalization Scale $2.3M $202.1M Larger Scale KROS
Trailing P/E Ratio Valuation N/M 48.8x Lower Multiple KROS
Forward P/E Ratio Valuation N/M 48.8x Lower Multiple KROS
Revenue Growth (YoY) Growth -87.2% +180.5% Higher Growth KROS
Operating Margin (TTM) Profitability -25032.0% -172.4% Higher Margin KROS
Net Profit Margin Profitability 0.0% -151.4% Higher Margin LYRA
Return on Equity (ROE) Capital Efficiency -404.5% -12.6% Higher ROE KROS
52-Week Range Position Momentum 1% ($0โ€“$38) 16% ($9โ€“$23) Stronger Trend KROS
Beta / 30D Volatility Risk Regime 0.33ฮฒ ยท 248% Vol 1.11ฮฒ ยท 67% Vol Lower Realized Risk KROS
Unified Institutional Score Composite Signal 52.2 / 100 (HOLD) 52.2 / 100 (HOLD) Higher Composite Tie

Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor

Full LYRA vs KROS Buy Guide
LYRA UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile N/A
IV Regime Unclassified
Live LYRA Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →
KROS CONSOLIDATION
92d in phase ยท OBV ACCUMULATION
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
IV Percentile 10th %ile
IV Regime Compressed (<25th %ile)
Live KROS Put/Call Gamma Walls & dealer positioning signals require Pro. Unlock 14-Day Free Trial →

Pillar 6 90-Day Technical & R&D Innovation Disclosures

Corporate R&D & Foundry Tracker
Neither LYRA nor KROS registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.